[시장보고서]미국의 말초신경자극기 시장 - 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 모달리티별, 접속성별, 용도별, 최종 용도별 부문 예측(2025-2033년)

미국의 말초신경자극기 시장 - 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 모달리티별, 접속성별, 용도별, 최종 용도별 부문 예측(2025-2033년)

U.S. Peripheral Nerve Stimulators Market Size, Share & Trends Analysis Report By Product Type (Systems, Wearables/Accessories), By Modality (Rechargeable, Non-rechargeable), By Connectivity, By Application, By End Use, And Segment Forecasts, 2025 - 2033

상품코드 : 1869734

리서치사 : Grand View Research

발행일 : 2025년 10월

페이지 정보 : 영문 300 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,845,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,332,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,305,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

시장 규모와 동향 :

미국의 말초신경자극기 시장 규모는 2024년 1억 514만 달러로 추정되었으며, 2033년까지 2억 5,336만 달러에 이를 것으로 예측됩니다.

2025년부터 2033년까지의 CAGR은 10.43%로 전망됩니다. 미국의 말초신경자극기 산업은 주로 만성 통증 질환의 유병률 증가, 저침습으로 표적화 된 통증 관리 요법에 대한 수요 증가 및 비 오피오이드 요법으로의 전환 확대에 의해 견인되었습니다.

의료 종사자와 환자 사이에서 말초신경자극 요법이 삶의 질 향상에 효과적이라는 인식이 높아지고 있는 것이 도입을 촉진하고 있습니다. 임베디드 시스템, 웨어러블 자극기, 고급 프로그램 기능 등의 기술적 진보가 시장 성장을 더욱 향상시키고 있습니다. 외래수술센터(ASC)와 통원 수술센터의 확대, 유리한 상환 정책, 수술 건수가 많은 고령화 인구 증가가 시장의 지속적인 성장에 기여하고 있습니다.

만성 질환의 유병률 상승은 미국의 말초신경자극기 산업의 성장을 지속적으로 견인하고 있습니다. 당뇨병, 비만, 고혈압, 천식, 만성 통증과 같은 질병을 가진 환자는 목표를 좁힌 장기 통증 관리 솔루션이 점점 더 필요하기 때문입니다. 말초신경자극기는 이러한 질병과 관련된 통증을 완화하는 저침습적 선택을 제공하여 환자의 치료 성과와 삶의 질을 향상시킵니다.

예를 들어 2025년 4월에 Health System Tracker가 지적한 바와 같이 미국은 타국에 비해 만성질환의 이환율이 높고, 비만과 당뇨병 환자수는 타국의 2배 이상, 천식 환자수는 1.7배, 우울증의 전체적인 부담도 큰 상황입니다. 이러한 만성 질환의 고환율은 선진 통증 관리 요법에 대한 수요를 증가시킬 뿐만 아니라 효과적이고 임상적으로 입증된 말초신경자극 솔루션의 필요성이 증가하고 있음을 보여줍니다. 2025년 7월 팬아메리칸 보건기구(PAHO) 보고서에 따르면 가장 많은 사인은 심혈관질환(216만명)이었고, 암(137만명), 당뇨병(42만명 이상), 만성 호흡기질환(41만6천명 이상)이 이어졌습니다. 자살은 15-29세의 젊은층에서 4번째로 많은 사인이며, 10만 760명의 생명을 빼앗았습니다.

시장 진출기업의 분류
주요 기업 프로파일
- B. Braun Medical Inc.
- Nalu Medical, Inc
- Curonix LLC.
- SPR
- Vygon
- AirLife
- Neuspera Medical
- Anesthesia Associates, Inc.
- AVNS
- Mercury Medical
- Medtronic
- Boston Scientific Corporation
- Abbott
- Bioventus
- Checkpoint Surgical Inc.
- Nervonik, Inc
기업의 시장 점유율 분석, 2024년
기타 주요 시장 기업 목록

JHS

영문 목차

영문목차

Market Size & Trends:

The U.S. peripheral nerve stimulators market size was estimated at USD 105.14 million in 2024 and is projected to reach USD 253.36 million by 2033, growing at a CAGR of 10.43% from 2025 to 2033. The U.S. peripheral nerve stimulators industry is primarily driven by the rising prevalence of chronic pain conditions and increasing demand for minimally invasive, targeted pain management therapies, and the growing shift toward non-opioid therapies.

Growing awareness among healthcare providers and patients about the effectiveness of peripheral nerve stimulation in improving quality of life is fueling adoption. Technological advancements, including implantable systems, wearable stimulators, and enhanced programmable features, further propel market growth. The expansion of outpatient and ambulatory surgery centers, favorable reimbursement policies, and an aging population with higher surgical volumes contribute to the sustained momentum of the market.

Rising prevalence of chronic diseases continues to drive growth in the U.S. peripheral nerve stimulators industry, as patients with conditions such as diabetes, obesity, hypertension, asthma, and chronic pain increasingly require targeted, long-term pain management solutions. Peripheral nerve stimulators offer minimally invasive options to alleviate pain associated with these illnesses, improving patient outcomes and quality of life.

For instance, in April 2025, Health System Tracker highlighted that the U.S. has a higher rate of chronic diseases compared to peer nations, with over twice as many people affected by obesity and diabetes, 1.7 times more with asthma, and an overall higher burden of depression. This elevated prevalence of chronic conditions not only increases demand for advanced pain management therapies but also underscores the growing need for effective, clinically proven peripheral nerve stimulation solutions. According to the Pan American Health Organization's (PAHO) report, in July 2025, cardiovascular diseases led with 2.16 million deaths, followed by cancer (1.37 million), diabetes (over 420,000), and chronic respiratory conditions (more than 416,000). Suicide, the fourth leading cause of death among youth aged 15-29, claimed 100,760 lives.

U.S. Peripheral Nerve Stimulators Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. peripheral nerve stimulators market report based on product type, modality, connectivity, application, and end use:

Product Type Outlook (Revenue, USD Million, 2021 - 2033)
Systems
Implantable
Non-implantable
- Handheld
- Others
Wearables/Accessories
Modality Outlook (Revenue, USD Million, 2021 - 2033)
Rechargeable
Non-rechargeable
Connectivity Outlook (Revenue, USD Million, 2021 - 2033)
Wired
Wireless
Application Outlook (Revenue, USD Million, 2021 - 2033)
Diabetic Peripheral Neuropathy Pain
Chronic Musculoskeletal Pain
Complex Regional Pain Syndrome (CRPS)
Headache and Migraine Disorders
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals and Clinics
Ambulatory Surgical Centers (ASCs)
Physiotherapy/Rehabilitation Centers
Others

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product Type
- 1.2.2. Modality
- 1.2.3. Connectivity
- 1.2.4. Application
- 1.2.5. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.5.5. Information Analysis
- 1.5.6. Data Analysis Models
1.6. Market Formulation & Data Visualization
1.7. Model Details
- 1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. U.S. Peripheral Nerve Stimulators Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. High and rising prevalence of chronic pain
  - 3.2.1.2. Shift away from opioids toward non-opioid/interventional therapies
  - 3.2.1.3. Evidence and real-world adoption showing clinical benefit
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. High device and procedure costs
  - 3.2.2.2. Technological limitations
- 3.2.3. Market Opportunities Analysis
  - 3.2.3.1. Outpatient centers and ambulatory surgery as key settings
  - 3.2.3.2. Aging population and comorbidities
- 3.2.4. Market Challenges Analysis
  - 3.2.4.1. Device-related risks and complications
  - 3.2.4.2. Intense market competition
3.3. U.S. Peripheral Nerve Stimulators Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Bargaining power of suppliers
  - 3.3.1.2. Bargaining power of buyers
  - 3.3.1.3. Threat of substitutes
  - 3.3.1.4. Threat of new entrants
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political & Legal Landscape
  - 3.3.2.2. Economic and Social Landscape
  - 3.3.2.3. Technological landscape

Chapter 4. U.S. Peripheral Nerve Stimulators Market: Product Type Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. U.S. Peripheral Nerve Stimulators Market Product Type Movement Analysis
4.3. U.S. Peripheral Nerve Stimulators Market Size & Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
4.4. Systems
- 4.4.1. Systems U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 4.4.1.1. Implantable U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 4.4.1.1.1. Handheld
    - 4.4.1.1.2. Others
  - 4.4.1.2. Non-implantable U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Wearables/Accessories
- 4.5.1. Wearables/Accessories U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Peripheral Nerve Stimulators Market: Modality Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. U.S. Peripheral Nerve Stimulators Market Modality Movement Analysis
5.3. U.S. Peripheral Nerve Stimulators Market Size & Trend Analysis, by Modality, 2021 to 2033 (USD Million)
5.4. Rechargeable
- 5.4.1. Rechargeable U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Non-rechargeable
- 5.5.1. Non-rechargeable U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Peripheral Nerve Stimulators Market: Connectivity Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. U.S. Peripheral Nerve Stimulators Market Connectivity Movement Analysis
6.3. U.S. Peripheral Nerve Stimulators Market Size & Trend Analysis, by Connectivity, 2021 to 2033 (USD Million)
6.4. Wired
- 6.4.1. Wired U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Wireless
- 6.5.1. Wireless U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Peripheral Nerve Stimulators Market: Application Estimates & Trend Analysis

7.1. Segment Dashboard
7.2. U.S. Peripheral Nerve Stimulators Market Connectivity Movement Analysis
7.3. U.S. Peripheral Nerve Stimulators Market Size & Trend Analysis, by Connectivity, 2021 to 2033 (USD Million)
7.4. Diabetic Peripheral Neuropathy Pain
- 7.4.1. Diabetic Peripheral Neuropathy Pain U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Chronic Musculoskeletal Pain
- 7.5.1. Chronic Musculoskeletal Pain U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Complex Regional Pain Syndrome (CRPS)
- 7.6.1. Complex Regional Pain Syndrome (CRPS) U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Headache and Migraine Disorders
- 7.7.1. Headache and Migraine Disorders U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. Others
- 7.8.1. Others U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Peripheral Nerve Stimulators Market: End-Use Estimates & Trend Analysis

8.1. Segment Dashboard
8.2. U.S. Peripheral Nerve Stimulators Market End-Use Movement Analysis
8.3. U.S. Peripheral Nerve Stimulators Market Size & Trend Analysis, by End-Use, 2021 to 2033 (USD Million)
8.4. Hospitals and Clinics
- 8.4.1. Hospitals and Clinics U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Ambulatory Surgical Centers (ASCs)
- 8.5.1. Ambulatory Surgical Centers (ASCs) U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Physiotherapy/Rehabilitation Centers
- 8.6.1. Physiotherapy/Rehabilitation Centers U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Others
- 8.7.1. Others U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Market Participant Categorization
9.2. Key Company Profiles
- 9.2.1. B. Braun Medical Inc.
  - 9.2.1.1. Company Overview
  - 9.2.1.2. Financial Performance
  - 9.2.1.3. Modality Benchmarking
  - 9.2.1.4. Strategic Initiatives
- 9.2.2. Nalu Medical, Inc
  - 9.2.2.1. Company Overview
  - 9.2.2.2. Financial Performance
  - 9.2.2.3. Modality Benchmarking
  - 9.2.2.4. Strategic Initiatives
- 9.2.3. Curonix LLC.
  - 9.2.3.1. Company Overview
  - 9.2.3.2. Financial Performance
  - 9.2.3.3. Modality Benchmarking
  - 9.2.3.4. Strategic Initiatives
- 9.2.4. SPR
  - 9.2.4.1. Company Overview
  - 9.2.4.2. Financial Performance
  - 9.2.4.3. Modality Benchmarking
  - 9.2.4.4. Strategic Initiatives
- 9.2.5. Vygon
  - 9.2.5.1. Company Overview
  - 9.2.5.2. Financial Performance
  - 9.2.5.3. Modality Benchmarking
  - 9.2.5.4. Strategic Initiatives
- 9.2.6. AirLife
  - 9.2.6.1. Company Overview
  - 9.2.6.2. Financial Performance
  - 9.2.6.3. Modality Benchmarking
  - 9.2.6.4. Strategic Initiatives
- 9.2.7. Neuspera Medical
  - 9.2.7.1. Company Overview
  - 9.2.7.2. Financial Performance
  - 9.2.7.3. Modality Benchmarking
  - 9.2.7.4. Strategic Initiatives
- 9.2.8. Anesthesia Associates, Inc.
  - 9.2.8.1. Company Overview
  - 9.2.8.2. Financial Performance
  - 9.2.8.3. Modality Benchmarking
  - 9.2.8.4. Strategic Initiatives
- 9.2.9. AVNS
  - 9.2.9.1. Company Overview
  - 9.2.9.2. Financial Performance
  - 9.2.9.3. Modality Benchmarking
  - 9.2.9.4. Strategic Initiatives
- 9.2.10. Mercury Medical
  - 9.2.10.1. Company Overview
  - 9.2.10.2. Financial Performance
  - 9.2.10.3. Modality Benchmarking
  - 9.2.10.4. Strategic Initiatives
- 9.2.11. Medtronic
  - 9.2.11.1. Company Overview
  - 9.2.11.2. Financial Performance
  - 9.2.11.3. Modality Benchmarking
  - 9.2.11.4. Strategic Initiatives
- 9.2.12. Boston Scientific Corporation
  - 9.2.12.1. Company Overview
  - 9.2.12.2. Financial Performance
  - 9.2.12.3. Modality Benchmarking
  - 9.2.12.4. Strategic Initiatives
- 9.2.13. Abbott
  - 9.2.13.1. Company Overview
  - 9.2.13.2. Financial Performance
  - 9.2.13.3. Modality Benchmarking
  - 9.2.13.4. Strategic Initiatives
- 9.2.14. Bioventus
  - 9.2.14.1. Company Overview
  - 9.2.14.2. Financial Performance
  - 9.2.14.3. Modality Benchmarking
  - 9.2.14.4. Strategic Initiatives
- 9.2.15. Checkpoint Surgical Inc.
  - 9.2.15.1. Company Overview
  - 9.2.15.2. Financial Performance
  - 9.2.15.3. Modality Benchmarking
  - 9.2.15.4. Strategic Initiatives
- 9.2.16. Nervonik, Inc
  - 9.2.16.1. Company Overview
  - 9.2.16.2. Financial Performance
  - 9.2.16.3. Modality Benchmarking
  - 9.2.16.4. Strategic Initiatives
9.3. Company Market Share Analysis, 2024
9.4. List of Other Key Market Players

한글목차

시장 규모와 동향 :

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 미국 말초신경자극기 시장의 변수, 동향 및 범위

제4장 미국의 말초 신경자극장치 시장 : 제품 유형별추정 및 동향 분석

제5장 미국의 말초신경자극기 시장 : 모달리티별 추정 및 동향 분석

제6장 미국의 말초신경자극기 시장 : 접속성별 추정 및 동향 분석

제7장 미국의 말초신경자극기 시장 : 용도별 추정 및 동향 분석

제8장 미국의 말초신경자극기 시장 : 최종 용도별 추정 및 동향 분석

제9장 경쟁 구도